Who are AEGR-733 and fenofibrate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aegr-733-and-fenofibrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AEGR-733 and fenofibrate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AEGR-733 and fenofibrate (AEGR-733 and fenofibrate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MTP inhibitor + fibrate combination. Area: Cardiovascular.

phase 2 MTP inhibitor + fibrate combination Microsomal triglyceride transfer protein (MTP) and PPARα Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AEGR-733 and fenofibrate (AEGR-733 and fenofibrate) — Aegerion Pharmaceuticals, Inc.. AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor combined with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, to reduce triglycerides and apolipoprotein B-containing lipoproteins.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AEGR-733 and fenofibrate TARGET	AEGR-733 and fenofibrate	Aegerion Pharmaceuticals, Inc.	phase 2	MTP inhibitor + fibrate combination	Microsomal triglyceride transfer protein (MTP) and PPARα

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MTP inhibitor + fibrate combination class)

Aegerion Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AEGR-733 and fenofibrate — Competitive Intelligence Brief. https://druglandscape.com/ci/aegr-733-and-fenofibrate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab